Safety and efficacy outcomes with erythropoiesisstimulating agents in patients with breast cancer: A meta-analysis

Matti Aapro, V. Moebus, U. Nitz, J. O'Shaughnessy, P. Pronzato, M. Untch, D. Tomita, C. Bohac, B. Leyland-Jones

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: New data on erythropoiesis-stimulating agents (ESAs) regarding overall survival and disease progressionrelated outcomes in patients with breast cancer receiving chemotherapy are presented in a meta-analysis of controlled trials of ESA use (epoetin α, epoetin β, darbepoetin α, biosimilars). Patients and methods: A literature search identified reports from January 1997 through March 2014. We used company databases for Amgen, Inc., or Janssen studies and published data for other studies. Random-effects odds ratios (ORs) were calculated to compare results for patients randomized to ESA with those randomized to control. Results: Deaths were reported for 571 of 2346 patients (24%) in the ESA groups and 523 of 2367 patients (22%) in the control groups [OR, 1.20; 95% confidence interval (CI) 1.03-1.40]. Sensitivity analyses were conducted to explore the effects of individual studies and exclusion of one study (BEST) resulted in an OR for death of 1.12 (95% CI 0.94-1.34). In seven studies reporting progression-related end points (N = 4197; ESA n = 2088; control n = 2109), the OR was 1.01 (95% CI 0.87-1.16) for ESA compared with control. Conclusions: After incorporating recent results of ESA use in patients with breast cancer, risks of survival and progression-free survival remain consistent with previously published data.

Original languageEnglish
Pages (from-to)688-695
Number of pages8
JournalAnnals of Oncology
Volume26
Issue number4
DOIs
Publication statusPublished - Apr 1 2015

Fingerprint

Hematinics
Proxy
Meta-Analysis
Breast Neoplasms
Safety
Odds Ratio
Confidence Intervals
Biosimilar Pharmaceuticals
Survival
Disease-Free Survival
Databases
Drug Therapy
Control Groups

Keywords

  • Breast cancer
  • Chemotherapy-induced anemia
  • Darbepoetin α
  • Epoetin α
  • Erythropoiesis-stimulating agents
  • Meta-analysis

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Medicine(all)

Cite this

Safety and efficacy outcomes with erythropoiesisstimulating agents in patients with breast cancer : A meta-analysis. / Aapro, Matti; Moebus, V.; Nitz, U.; O'Shaughnessy, J.; Pronzato, P.; Untch, M.; Tomita, D.; Bohac, C.; Leyland-Jones, B.

In: Annals of Oncology, Vol. 26, No. 4, 01.04.2015, p. 688-695.

Research output: Contribution to journalArticle

Aapro, M, Moebus, V, Nitz, U, O'Shaughnessy, J, Pronzato, P, Untch, M, Tomita, D, Bohac, C & Leyland-Jones, B 2015, 'Safety and efficacy outcomes with erythropoiesisstimulating agents in patients with breast cancer: A meta-analysis', Annals of Oncology, vol. 26, no. 4, pp. 688-695. https://doi.org/10.1093/annonc/mdu579
Aapro, Matti ; Moebus, V. ; Nitz, U. ; O'Shaughnessy, J. ; Pronzato, P. ; Untch, M. ; Tomita, D. ; Bohac, C. ; Leyland-Jones, B. / Safety and efficacy outcomes with erythropoiesisstimulating agents in patients with breast cancer : A meta-analysis. In: Annals of Oncology. 2015 ; Vol. 26, No. 4. pp. 688-695.
@article{60c957f12d7b4d4297a02d24e4d4698e,
title = "Safety and efficacy outcomes with erythropoiesisstimulating agents in patients with breast cancer: A meta-analysis",
abstract = "Background: New data on erythropoiesis-stimulating agents (ESAs) regarding overall survival and disease progressionrelated outcomes in patients with breast cancer receiving chemotherapy are presented in a meta-analysis of controlled trials of ESA use (epoetin α, epoetin β, darbepoetin α, biosimilars). Patients and methods: A literature search identified reports from January 1997 through March 2014. We used company databases for Amgen, Inc., or Janssen studies and published data for other studies. Random-effects odds ratios (ORs) were calculated to compare results for patients randomized to ESA with those randomized to control. Results: Deaths were reported for 571 of 2346 patients (24{\%}) in the ESA groups and 523 of 2367 patients (22{\%}) in the control groups [OR, 1.20; 95{\%} confidence interval (CI) 1.03-1.40]. Sensitivity analyses were conducted to explore the effects of individual studies and exclusion of one study (BEST) resulted in an OR for death of 1.12 (95{\%} CI 0.94-1.34). In seven studies reporting progression-related end points (N = 4197; ESA n = 2088; control n = 2109), the OR was 1.01 (95{\%} CI 0.87-1.16) for ESA compared with control. Conclusions: After incorporating recent results of ESA use in patients with breast cancer, risks of survival and progression-free survival remain consistent with previously published data.",
keywords = "Breast cancer, Chemotherapy-induced anemia, Darbepoetin α, Epoetin α, Erythropoiesis-stimulating agents, Meta-analysis",
author = "Matti Aapro and V. Moebus and U. Nitz and J. O'Shaughnessy and P. Pronzato and M. Untch and D. Tomita and C. Bohac and B. Leyland-Jones",
year = "2015",
month = "4",
day = "1",
doi = "10.1093/annonc/mdu579",
language = "English",
volume = "26",
pages = "688--695",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "4",

}

TY - JOUR

T1 - Safety and efficacy outcomes with erythropoiesisstimulating agents in patients with breast cancer

T2 - A meta-analysis

AU - Aapro, Matti

AU - Moebus, V.

AU - Nitz, U.

AU - O'Shaughnessy, J.

AU - Pronzato, P.

AU - Untch, M.

AU - Tomita, D.

AU - Bohac, C.

AU - Leyland-Jones, B.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background: New data on erythropoiesis-stimulating agents (ESAs) regarding overall survival and disease progressionrelated outcomes in patients with breast cancer receiving chemotherapy are presented in a meta-analysis of controlled trials of ESA use (epoetin α, epoetin β, darbepoetin α, biosimilars). Patients and methods: A literature search identified reports from January 1997 through March 2014. We used company databases for Amgen, Inc., or Janssen studies and published data for other studies. Random-effects odds ratios (ORs) were calculated to compare results for patients randomized to ESA with those randomized to control. Results: Deaths were reported for 571 of 2346 patients (24%) in the ESA groups and 523 of 2367 patients (22%) in the control groups [OR, 1.20; 95% confidence interval (CI) 1.03-1.40]. Sensitivity analyses were conducted to explore the effects of individual studies and exclusion of one study (BEST) resulted in an OR for death of 1.12 (95% CI 0.94-1.34). In seven studies reporting progression-related end points (N = 4197; ESA n = 2088; control n = 2109), the OR was 1.01 (95% CI 0.87-1.16) for ESA compared with control. Conclusions: After incorporating recent results of ESA use in patients with breast cancer, risks of survival and progression-free survival remain consistent with previously published data.

AB - Background: New data on erythropoiesis-stimulating agents (ESAs) regarding overall survival and disease progressionrelated outcomes in patients with breast cancer receiving chemotherapy are presented in a meta-analysis of controlled trials of ESA use (epoetin α, epoetin β, darbepoetin α, biosimilars). Patients and methods: A literature search identified reports from January 1997 through March 2014. We used company databases for Amgen, Inc., or Janssen studies and published data for other studies. Random-effects odds ratios (ORs) were calculated to compare results for patients randomized to ESA with those randomized to control. Results: Deaths were reported for 571 of 2346 patients (24%) in the ESA groups and 523 of 2367 patients (22%) in the control groups [OR, 1.20; 95% confidence interval (CI) 1.03-1.40]. Sensitivity analyses were conducted to explore the effects of individual studies and exclusion of one study (BEST) resulted in an OR for death of 1.12 (95% CI 0.94-1.34). In seven studies reporting progression-related end points (N = 4197; ESA n = 2088; control n = 2109), the OR was 1.01 (95% CI 0.87-1.16) for ESA compared with control. Conclusions: After incorporating recent results of ESA use in patients with breast cancer, risks of survival and progression-free survival remain consistent with previously published data.

KW - Breast cancer

KW - Chemotherapy-induced anemia

KW - Darbepoetin α

KW - Epoetin α

KW - Erythropoiesis-stimulating agents

KW - Meta-analysis

UR - http://www.scopus.com/inward/record.url?scp=84926452265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926452265&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdu579

DO - 10.1093/annonc/mdu579

M3 - Article

C2 - 25542926

AN - SCOPUS:84926452265

VL - 26

SP - 688

EP - 695

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 4

ER -